CLL14 trial thoughts

(1:14)

Novel Insights from the Randomized, Phase 3 CLL14 Trial

(2:21)

CLL14 trial analysis

(3:7)

CLL14 trial: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil

(4:30)

Dr. Mato on the CLL14 Trial Results in CLL

(1:10)

Obinutuzumab and venetoclax for high-risk CLL: upcoming CLL14 trial

(45)

Dr. Raphael on the Clinical Implications of the CLL14 Trial

(1:5)

CLL14: feasibility of fixed-duration frontline therapy in CLL

(1:32)

Kirsten Fischer, Treatment of CLL from 2019 Onwards: CLL14 Trial

(9:29)

CLL14 trial: do certain patients benefit more from venetoclax plus obinutuzumab in CLL?

(3:8)

Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL

(1:43)

Dr. Siddiqi on the CLL14 Trial Results in CLL

(1:7)

CLL14: Venetoclax plus obinutuzumab for CLL

(5:54)

Dr. Shadman on the CLL14 Trial in CLL

(1:31)

Othman Al Sawaf, ASCO20: Results of the Phase III CLL14 Trial for Chronic Lymphocytic Leukaemia

(7:59)

Venetoclax plus obinutuzumab in CKT CLL: analysis from the CLL14 trial

(1:24)

Othman Al-Sawaf, EHA, 2019 – Analysis of the CLL14 trial

(6:37)

Lori A. Leslie, MD, elaborates on recent outcomes from the CLL14 trial

(1:16)

Updates from the CLL14 and CLL2-GiVe trials on CLL

(1:3)